Global Male Hypogonadism Pipeline Review 2016 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Male Hypogonadism - Pipeline Review, H1 2016" report to their offering.

This report provides comprehensive information on the therapeutic development for Male Hypogonadism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Male Hypogonadism and special features on late-stage and discontinued projects.

The report enhances decision-making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MoAs to produce first-in-class and best-in-class products.

Key Topics Covered:

  1. Introduction
  2. Male Hypogonadism Overview
  3. Therapeutics Development
  4. Pipeline Products for Male Hypogonadism - Overview
  5. Pipeline Products for Male Hypogonadism - Comparative Analysis
  6. Male Hypogonadism - Therapeutics under Development by Companies
  7. Male Hypogonadism - Therapeutics under Investigation by Universities/Institutes
  8. Male Hypogonadism Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Male Hypogonadism - Products under Development by Companies
  13. Male Hypogonadism - Products under Investigation by Universities/Institutes
  14. Male Hypogonadism - Companies Involved in Therapeutics Development
  • Antares Pharma, Inc.
  • Clarus Therapeutics, Inc.
  • Diurnal Limited
  • EndoCeutics, Inc.
  • Ferring International Center S.A.
  • Forendo Pharma Limited
  • Lipocine Inc.
  • M et P Pharma AG
  • Merck & Co., Inc.
  • Mereo Biopharma Group Limited
  • Millennium Pharmaceuticals, Inc.
  • Monosol Rx, LLC
  • Pantarhei Bioscience BV
  • Repros Therapeutics Inc.
  • Variant Pharmaceuticals, Inc.

For more information visit http://www.researchandmarkets.com/research/t2k3k5/male_hypogonadism

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716